AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
Date of Report: July 18, 2014
Company: AbbVie Inc.
Event: Entry into a Material Definitive Agreement regarding a recommended combination with Shire plc.
On July 18, 2014, AbbVie and Shire plc announced an agreement to combine. The transaction involves a court-sanctioned scheme of arrangement for Shire shareholders and a merger for AbbVie shareholders. Both entities will become wholly owned indirect subsidiaries of a new entity, "New AbbVie," intended to be listed on the New York Stock Exchange.
Key Financial Metrics and Agreements
This filing details the terms of the combination and financing arrangements rather than historical operating results.
- Consideration for Shire Shareholders: £24.44 in cash and 0.8960 shares of New AbbVie per Shire share.
- Consideration for AbbVie Shareholders: One share of New AbbVie for each AbbVie share held.
- Bridge Credit Facility: A £13.5 billion facility entered into on July 17, 2014, with JPMorgan Chase Bank, N.A. as administrative agent.
- Facility Structure:
- Tranche 1: Up to £9.1 billion
- Tranche 2: Up to £3.2 billion
- Tranche 3: Up to £1.2 billion
- Interest Rates: Base Rate Loans (0.0% to 0.50% margin) or Eurocurrency Rate Loans (0.625% to 1.50% margin), dependent on credit ratings.
- Maturity: Tranche 1 and 2 mature 364 days after the Closing Date; Tranche 3 matures 60 days after the Closing Date. Commitments terminate in full by July 31, 2015.
Material Changes and Transaction Conditions
The combination is subject to several material conditions, including:
- Approval of the Scheme by Shire shareholders.
- Sanction of the Scheme by a Jersey court.
- Adoption of the Merger Agreement by AbbVie shareholders.
- Receipt of necessary regulatory approvals.
Timeline: Completion is expected in the fourth quarter of 2014, subject to conditions. The Co-operation Agreement includes a termination right for AbbVie if the Scheme is not consummated by April 30, 2015.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The transaction is structured to create a new combined entity (New AbbVie). AbbVie retains the right to elect a takeover offer instead of the Scheme, subject to U.K. Panel consent.
Risks and Contingencies:
- Financing Risk: The Bridge Credit Facility is intended to finance the cash consideration if new senior unsecured notes are not issued prior to consummation.
- Regulatory Risk: The deal is contingent on regulatory clearances.
- Excise Tax Indemnification: Due to the combination, Section 4985 of the Internal Revenue Code imposes a 15% excise tax on certain equity compensation for Section 16 officers. AbbVie has agreed to indemnify these individuals to ensure they are in the same net after-tax position as if the tax did not apply.
Investor Verification Checklist
- Verify the final approval status of the Scheme by Shire shareholders and the Jersey court.
- Confirm the receipt of all required regulatory approvals from relevant jurisdictions.
- Monitor the issuance of permanent senior unsecured notes to replace the £13.5 billion bridge facility.
- Review the full text of the Rule 2.7 Announcement (Exhibit 2.1) for detailed conditions precedent.
- Assess the impact of the 15% excise tax indemnification on AbbVie's future compensation expenses.